glp-1 cigna coverage Weight Loss Drugs: Under Medicaid and Other Health Plans What to know about GLP-1

While concerns about pancreatic safety exist, the overall risk appears to be minimal, and the health risks of having obesity justify the use of GLP-1s

#PharmaMarketing #MedicalRepresentative #Leadership #PharmaSales #HealthcareMarketing To view or add a comment, sign in Government affairs is a top-of-mind issue for biopharma C-suites today as they seek to continue growth amid policy discussion and geopolitical tensions

Margraf A, Ludwig N, Zarbock A, Rossaint J

A total of 116 million records from patients 12 years old and older with type 2 diabetes and those considered overweight or obese (by high BMI), with at least one ophthalmology or neurology visit, were included

Both patients with AD and disease models exhibit significant downregulation of LONP1 expression in brain tissues, accompanied by dysregulation of mitochondrial protein homeostasis networks